1. Introduction {#sec1}
===============

In vivo drug clearance is a very significant pharmacokinetic parameter, which largely determines the drug exposure in human body \[[@B1], [@B2]\]. Predicting the clinical in vivo drug clearance from the preclinical in vitro experiments is essential during the drug development. Specifically, hepatic clearance (CL~H~) is the most important clearance parameter as the majority of the drugs are metabolized in human liver \[[@B3]\].

The most common in vitro drug clearance methods include the use of human liver microsomes (HLMs) or hepatocytes \[[@B4]\], which are well documented in the literature \[[@B5]--[@B8]\]. The advantage of HLMs and human hepatocytes is that they are physiologically closer to human liver \[[@B4], [@B9], [@B10]\]. Their disadvantages include enormous problems between sample variations with unknown causes and relative high expense \[[@B11], [@B12]\]. In particular, the large variation of in vitro experiments in HLMs or hepatocytes causes the doubts in reproducibility. On the other hand, the commercial availability of recombinant human enzyme expression systems makes the prediction of human drug clearance cheaper and more reproducible \[[@B13], [@B14]\]. The advantages and limitations of each in vitro approach are well documented \[[@B15]--[@B21]\].

In order to predict in vivo clearance from in vitro experiments, system pharmacology model, such as the physiologically based pharmacokinetic (PBPK) model have been developed rapidly \[[@B22]--[@B25]\]. Yap et al. \[[@B26]\] present statistical learning models based on mixed physicochemical and topological descriptors. Demir-Kavuk et al. \[[@B27]\] develop a single application called DemQSAR. Simcyp \[[@B28]\] and Gastroplus \[[@B29]\] are developed originally in collaboration with major pharmaceutical companies to simulate and predict drug clearance and drug interaction in virtual patient populations.

Despite the previously described advances in both technology and system pharmacology modeling, in vitro drug clearance prediction still faces some new challenges \[[@B25], [@B30]\]. There are a number of in vitro recombinant enzyme systems available, but it is not clear whether they all perform similarly or differently. The performance of different recombinant systems can also be enzyme dependent, but little was known about it \[[@B30]\]. Finally and most importantly, unlike traditional physiologically based pharmacokinetics modeling that investigates one or a few drugs a time, current translational bioinformatics desires a system model that can conduct large scale drug clearance for all the drugs \[[@B31]\]. This is a new challenge that poses not only the accuracy of the in vitro-in vivo clearance prediction, but also the completeness and variations of the annotated in vitro recombinant experiment data on drug metabolisms. As the in vitro-in vivo clearance prediction has been well documented in the literature, this paper will address the completeness and variations of various in vitro recombinant experiments.

2. Methods {#sec2}
==========

2.1. In Vitro Experimental Data Collection {#sec2.1}
------------------------------------------

All the in vitro data of selected drugs were collated from the published literature after identifying sources using PubMed. The criteria for drug selection were that they were recognized as probes for specific cytochrome P450s (CYP) or metabolized mostly by a single CYP enzyme \[[@B32], [@B33]\]. Probe drugs refer to drugs whose plasma AUC values had been shown to increase 5-fold or higher when coadministered with a known CYP inhibitor or AUC ratio in poor metabolizers versus 1280 extensive metabolizers is greater than 5-fold \[[@B33]\]. These literature data including *V* ~max⁡~ (pmol min^−1 ^pmol^−1^CYP), *K* ~*m*~ (pM) were obtained from various systems for heterologous expression of recombinant P450 enzymes containing bacterial expression in*Escherichia coli*, expression in yeast cells, lymphoblastoid expression systems, and baculovirus-driven expression in insect cells. Fraction unbound in plasma (fu) of drugs was also collected. If intervals of the fraction of drug unbound in plasma parameters were collected, the mean of an interval was the acceptable value.

2.2. In Vivo Data Collection {#sec2.2}
----------------------------

Human clearance values were taken from published original work and in part reported by Obach et al. \[[@B34]\]. Both intravenous data and oral data were accepted. In the case of oral clearance, the clearance was taken as a product of oral clearance and absolute bioavailability of the drug, in order to calculate drugs\' intravenous clearance. The bioavailability was got through Drug Bank \[[@B35]\] and published original literature with a single point or the mean of an interval. At the end, only the intravenous clearance was used to assess in vitro-in vivo clearance prediction.

2.3. In Vitro-In Vivo Extrapolation {#sec2.3}
-----------------------------------

Prediction of drug hepatic clearance using in vitro recombinant P450 enzyme kinetic parameters was performed in three main steps. Initially, intrinsic clearance per unit enzyme (CL~int,rec~) was calculated by the following: $$\begin{matrix}
{\text{C}\text{L}_{{int},\text{rec}} = \frac{v_{\max}}{k_{m}}.} \\
\end{matrix}$$ The median CL~int,rec~ value of the same recombinant P450 enzymes expression systems for each drug was taken, respectively.

After that, CL~int,rec~ was converted to a whole organ intrinsic metabolic clearance (CL~int~) using enzyme abundance, MPPGL, and the liver weight as shown in the following: $$\begin{matrix}
{\text{C}\text{L}_{int} = \left( {\sum\limits_{j = 1}^{m}{\text{C}\text{L}_{{int},\text{rec}} \cdot \text{enzyme}\,\,\text{abundance}}} \right)} \\
{\quad \cdot \text{MPPGL} \cdot \text{liver}\,\,\text{weight},} \\
\end{matrix}$$ where there were *m* CYPs with corresponding CL~int,rec~ values for different pathways in each recombinant system; enzyme abundance refers to the amount (pmol P450) per milligram of microsomal protein; MPPGL means the amount (mg) of microsomal protein per gram of liver; and the liver weight means the weight (g) of human liver. Enzyme abundance, MPPGL, liver weight, and liver blood flow were generated by Simcyp with 1000 Sim-healthy volunteers (age: 20--50), female/male ratio 1, and 100% of extensive metabolizer for all major CYP enzymes \[[@B36]\].

At last, the value of CL~int~ was combined with binding parameters (*f* ~ub~) and liver blood flow (*Q* ~H~) to extrapolate to whole organ clearance by well-stirred model by the following: $$\begin{matrix}
{\text{C}\text{L}_{\text{H}} = \frac{\text{C}\text{L}_{int} \times Q_{\text{H}} \times f_{\text{ub}}}{\text{C}\text{L}_{int} + Q_{\text{H}} \times f_{\text{ub}}},} \\
\end{matrix}$$ where *f* ~ub~ is the fraction of drug unbound in blood. So, it could be calculated by *f* ~u~/*B*/*P* ratios. While *B*/*P* ratios were not all available from the literature, a default value of 0.55 was used. Meanwhile, nonspecific microsomal binding was ignored.

2.4. Scaling Factor {#sec2.4}
-------------------

The scaling factor of each probe drug was assessed from the difference between predicted and observed in vivo values as described in the following: $$\begin{matrix}
{\text{Scaling}\,\,\text{Factor} = {{\log}_{2}\left( \frac{\text{C}\text{L}_{\text{H},\text{in}\,\text{vivo}}}{\text{C}\text{L}_{\text{H},\text{predicted}}} \right)},} \\
\end{matrix}$$ where CL~H,in vivo~ is the observed in vivo clearance and CL~H,predicted~ is the predicted value. Then, the scaling factor for different enzymes was determined by averaging scaling factor of probe drugs with the same recombinant P450 enzymes expression systems. This value also could assess the accuracy of clearance predicting. For one drug, if the scaling factor in one system was identical to the others, they had the same accuracy in predicting.

2.5. Statistical Analysis {#sec2.5}
-------------------------

All data were presented as mean ± S.E., unless stated otherwise. To measure the variability of prediction, the coefficient of variation (CV) was utilized. This CV measures the technical variations of in vitro metabolism experiments published from different labs.

3. Results {#sec3}
==========

3.1. Literature Data Collection {#sec3.1}
-------------------------------

Thirty-five drugs were considered as probe drugs for various enzymes, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A, from different expression systems as they had relatively adequate kinetic data, as shown in [Table 1](#tab1){ref-type="table"} \[[@B32], [@B33]\].

3.2. Comparison of Clearance Predictions for Different Enzyme Probe Drugs from the Same Expression System {#sec3.2}
---------------------------------------------------------------------------------------------------------

Since most drugs had baculovirus system data, they were used to predict probe drugs\' clearance. The predicted clearance was within 3-fold of the observed in vivo value for 6 of the 15 (40%) drugs for CYP3A probe drugs. While for CYP 2D6, none of the predicted values was within 3-fold the observed in vivo value. Only one drug was within 3-fold the observed value for CYP1A2, 2B6, 2C8, 2C9, and 2C19, which accounted for 50%, 50%, 50%, 50%, and 33% of the total. These results were illustrated in [Figure 1](#fig1){ref-type="fig"} and [Table 2](#tab2){ref-type="table"}.

3.3. Comparisons of Clearance Predictions in the Different Expression Systems {#sec3.3}
-----------------------------------------------------------------------------

Dextromethorphan and midazolam were selected to compare different expression systems, because these two drugs were investigated and published under all these systems. For dextromethorphan, the predicted values from yeast system were only within 3-fold the in vivo value. And baculovirus system and lymphoblastoid system had almost the same prediction accuracy ([Figure 2](#fig2){ref-type="fig"}, [Table 2](#tab2){ref-type="table"}).

For midazolam, all of the predicted clearance values were within 3-fold the in vivo clearance values. The most accurate predicted value was from*E. coli* system. And the three expression systems had almost the same prediction accuracy ([Figure 2](#fig2){ref-type="fig"}, [Table 2](#tab2){ref-type="table"}).

3.4. Comparison of Data Availability from Different Expression Systems {#sec3.4}
----------------------------------------------------------------------

All the in vitro recombinant enzyme expression system data were collated from the published literature. The total number of data points was 293. [Figure 3](#fig3){ref-type="fig"} showed the proportion of data from different expression systems. In general, baculovirus and lymphoblastoid system were more abundant than the others. Baculovirus system has the largest proportion, 67%. Lymphoblastoid system was the second one, 20%. Only 8% and 5% of the data came from*E. coli* system and yeast system.

If we mapped all the data to different drugs, the majority of the drugs (28/35) were tested in the baculovirus expression system; part (12/35) of the selected drugs were test in the lymphoblastoid expression systems and only 4/35 were from*E. coli*and yeast systems, respectively.

3.5. Comparisons of Scaling Factors {#sec3.5}
-----------------------------------

Scaling factors of different enzymes based on CYP expression systems were calculated and shown in [Table 3](#tab3){ref-type="table"}. These scaling factor ranged from −1.735 to 3.794. In the baculovirus expression system, the values of scaling factors varied a lot across the enzymes ([Figure 4](#fig4){ref-type="fig"}). And 71.4% (5/7) of the values, whose range was −1.735 to 2.394, were positive.

The variability in the same enzyme between CYP expression systems was also different. In CYP2D6, yeast system and lymphoblastoid system had higher variability than baculovirus system with the coefficient of variation (CV) 65.13%, 87.95%, and 25.10%, respectively. In CYP3A, lymphoblastoid system (CV = 356.60%) had higher variability than baculovirus system (CV = 200.98%) similarly. However, in CYP2C9 the coefficient of variation in lymphoblastoid (CV = 153.66%) was smaller than baculovirus system (CV = 368.53%).

4. Discussion and Conclusion {#sec4}
============================

In this paper, we compare the performance of different recombinant human enzyme expression systems (including*Escherichia coli* system, yeast system, lymphoblastoid system, and baculovirus system) for predicting hepatic clearance in human body. And we attempt to find out the most suitable one for the large scale drug clearance prediction. After collecting the in vitro pharmacokinetic parameters of thirty-five probe drugs, we use in vitro-in vivo extrapolation to predict the clearance. The experimental results ([Table 2](#tab2){ref-type="table"}) show that half (24/48) of the predicted values in different in vitro systems are within 3-fold the observed in vivo clearance values.

The comparisons of clearance predictions for different enzyme probe drugs from the same expression system and in different expression systems, data availability from different expression systems, and scaling factors are further analyzed. [Figure 2](#fig2){ref-type="fig"} shows that baculovirus system has almost equal accuracy as the other systems in predicting clearance. Meanwhile, it can provide more and sufficient data for prediction than the others ([Figure 3](#fig3){ref-type="fig"}). We should note that the scaling factor will be enzyme dependent as shown in [Table 3](#tab3){ref-type="table"} and in most cases baculovirus systems have the smaller CV in scaling factors. Therefore, we shall use data of the baculovirus system for the large scale drug clearance prediction.

Nevertheless, there are a few more caveats. Most important of all is that in vivo clearance of some probe drugs we collected contains the renal clearance. Some of the in vivo clearance is obtained as the systemic clearance. And the proportion of hepatic metabolism was not clear. Hence, the scaling factor estimation may have some bias.

In most closely related studies, the combination of HLM and recombinant enzymes is implemented to predict in vivo clearance for high accuracy of in vitro-in vivo extrapolation \[[@B37]--[@B39]\]. But most of them only focused on one drug, and the choice of in vitro systems was not taken into consideration.

We are fully aware that some drugs are metabolized through non-CYP pathways, such as oxidases, reductases, and other phase II metabolism enzymes. Our preliminary research on these enzymes revealed very limited in vitro experiment data on only a handful of drugs. Therefore, these data cannot be scaled up to do large scale in vitro-in vivo prediction and to evaluate their variations.

To our knowledge, this is the first study to compare the performance of different in vitro systems and make a decision. With the assistance of our work, the large scale drug clearance prediction should be more effective and efficient.
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###### 

Drug set.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                 Expression systems                                  In vivo clearance\   References
                                                                                           (L/h)                
  ------------------------------------ --------------------------------------------------- -------------------- -----------------------------------------------------------------------------
  Caffeine                             Baculovirus                                         5.88                 Obach et al. (2008) \[[@B34]\]

  Melatonin                            Baculovirus                                         57.96                Mallo et al. (1990) \[[@B40]\]

  Tacrine                              Yeast                                               235.2                Obach et al. (2008) \[[@B34]\]

  Theophylline (1,3-DMX)               *E. coli* and lymphoblastoid                        3.612                Obach et al. (2008) \[[@B34]\]

  Bupropion                            Baculovirus                                         5.415                Lei et al. (2010) \[[@B41]\], Hill et al. (2007) \[[@B42]\]

  Efavirenz                            Baculovirus                                         5.483                Gengiah et al. (2012) \[[@B43]\], Chiappetta et al. (2010) \[[@B44]\]

  Repaglinide                          Baculovirus                                         32.76                Obach et al. (2008) \[[@B34]\]

  Paclitaxel                           Baculovirus                                         26.88                Obach et al. (2008) \[[@B34]\]

  (R)-Warfarin                         Baculovirus, *E. coli*, and lymphoblastoid          0.231                Obach et al. (2008) \[[@B34]\]

  Phenytoin                            Baculovirus and lymphoblastoid                      3.906                Hayes et al. (1975) \[[@B45]\]

  Celecoxib                            Lymphoblastoid and yeast                            21.05                Drug Bank \[[@B35]\], Paulson et al. (2001) \[[@B46]\]

  Clobazam                             Baculovirus                                         2.49                 Drug Bank \[[@B35]\]

  (R)-Lansoprazole (dexlansoprazole)   Baculovirus                                         18.48                Obach et al. (2008) \[[@B34]\]

  (R)-Omeprazole                       Baculovirus and lymphoblastoid                      35.28                Obach et al. (2008) \[[@B34]\]

  Atomoxetine                          Baculovirus                                         15.435               Drug Bank \[[@B35]\]

  Dextromethorphan                     Baculovirus, *E. coli*, yeast, and lymphoblastoid   40.59                Moghadamnia et al. (2003) \[[@B47]\], Kukanich and Papich (2004) \[[@B48]\]

  Metoprolol                           Lymphoblastoid                                      54.6                 Obach et al. (2008) \[[@B34]\]

  Perphenazine                         Baculovirus                                         113.4                Obach et al. (2008) \[[@B34]\]

  Tolterodine                          Baculovirus                                         10.5                 Brynne et al. (1997) \[[@B49]\]

  Venlafaxine                          Lymphoblastoid and yeast                            40.95                Drug Bank \[[@B35]\]

  Alfentanil                           Baculovirus                                         16.38                Obach et al. (2008) \[[@B34]\]

  Astemizole                           Yeast                                               82.6                 Lefebvre et al. (1997) \[[@B50]\]

  Cisapride                            Baculovirus                                         14.20                Lowry et al. (2003) \[[@B51]\]

  Cyclosporine                         Baculovirus                                         31.5                 Obach et al. (2008) \[[@B34]\]

  Felodipine                           Baculovirus and lymphoblastoid                      46.2                 Obach et al. (2008) \[[@B34]\]

  Indinavir                            Baculovirus                                         75.6                 Obach et al. (2008) \[[@B34]\]

  Maraviroc                            Baculovirus                                         44                   Abel et al (2008) \[[@B52]\]

  Midazolam                            Baculovirus, *E. coli*, and lymphoblastoid          22.26                Obach et al. (2008) \[[@B34]\]

  Pimozide                             Baculovirus                                         0.042                Desta et al. (1999) \[[@B53]\]

  Quinidine                            Lymphoblastoid                                      16.8                 Obach et al. (2008) \[[@B34]\]

  Sildenafil                           Baculovirus                                         38.22                Obach et al. (2008) \[[@B34]\]

  Sirolimus                            Baculovirus                                         2.73                 Brattstram et al. (2000) \[[@B54]\]

  Tacrolimus                           Baculovirus                                         4.63                 Obach et al. (2008) \[[@B34]\]

  Triazolam                            Baculovirus and lymphoblastoid                      12.6                 Obach et al. (2008) \[[@B34]\]

  Vardenafil                           Baculovirus                                         54.6                 Obach et al. (2008) \[[@B34]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Predicted value and observed in vivo value of probe drugs.

  Drug                                 Expression systems   The predicted value (L/h)   The observed in vivo value (L/h)   Scaling factor
  ------------------------------------ -------------------- --------------------------- ---------------------------------- ----------------
  Caffeine                             Baculovirus          1.21                        5.88                               2.28
  (R)-Lansoprazole (dexlansoprazole)   Baculovirus          81.74                       18.48                              −2.12
  (R)-Omeprazole                       Baculovirus          31.81                       35.28                              0.15
  (R)-Omeprazole                       Lymphoblastoid       15.56                       35.28                              1.18
  (R)-Warfarin                         Baculovirus          0.66                        0.231                              −1.51
  (R)-Warfarin                         *E.coli*             0.0041                      0.231                              5.82
  (R)-Warfarin                         Lymphoblastoid       0.018                       0.1512                             3.07
  7-Epi-10-deacetyl-paclitaxel         Baculovirus          1.77                        26.88                              3.93
  Alfentanil                           Baculovirus          56.32                       16.38                              −1.79
  Astemizole                           Yeast                40.24                       82.6                               1.04
  Atomoxetine                          Baculovirus          1.65                        20.99875                           3.67
  Bupropion                            Baculovirus          7.27                        5.415                              −0.43
  Celecoxib                            Lymphoblastoid       41.26                       21.05                              −0.97
  Celecoxib                            Yeast                5.66                        21.05                              1.90
  Cisapride                            Baculovirus          20.76                       14.1975                            −0.56
  Clobazam                             Baculovirus          23.02                       2.49                               −3.18
  Cyclosporine                         Baculovirus          29.07                       31.5                               0.11
  Dextromethorphan                     Baculovirus          11.53                       15.435                             0.42
  Dextromethorphan                     *E.coli*             0.26                        15.435                             5.89
  Dextromethorphan                     Lymphoblastoid       11.87                       15.435                             0.38
  Dextromethorphan                     Yeast                21.66195                    15.435                             −0.49
  Efavirenz                            Baculovirus          0.19                        5.483                              4.85
  Felodipine                           Lymphoblastoid       0.83                        46.2                               5.80
  Indinavir                            Baculovirus          89.11                       75.6                               −0.23
  Maraviroc                            Baculovirus          33.78                       44                                 0.38
  Melatonin                            Baculovirus          35.52                       57.96                              0.70
  Metoprolol                           Lymphoblastoid       44.05                       54.6                               0.31
  Midazolam                            Baculovirus          54.9                        22.26                              −1.29
  Midazolam                            *E.coli*             44.97                       22.26                              −1.03
  Midazolam                            Lymphoblastoid       46.51                       22.26                              −1.06
  Perphenazine                         Baculovirus          34.35                       113.4                              1.72
  Phenytoin                            Baculovirus          0.37                        3.906                              3.40
  Phenytoin                            Lymphoblastoid       1.07                        3.906                              1.87
  Pimozide                             Baculovirus          6.87                        0.042471                           −6.64
  Quinidine                            Lymphoblastoid       76.93                       16.8                               −2.18
  Repaglinide                          Baculovirus          27.29                       32.76                              0.26
  Sildenafil                           Baculovirus          5.17                        38.22                              2.89
  Sirolimus                            Baculovirus          19.47                       2.73                               −2.84
  Tacrine                              Yeast                16.96                       235.2                              3.79
  Tacrolimus                           Baculovirus          89.11                       4.634                              −4.32
  Theophylline (1,3-DMX)               *E. coli*            6.6                         3.612                              −0.86
  Theophylline (1,3-DMX)               Lymphoblastoid       8.04                        3.612                              −1.15
  Tolterodine                          baculovirus          2.22                        10.5                               2.24
  Triazolam                            Baculovirus          46.65                       12.6                               −1.89
  Triazolam                            Lymphoblastoid       4.65                        12.6                               1.44
  Vardenafil                           Baculovirus          27.75                       54.6                               0.98
  Venlafaxine                          Lymphoblastoid       13.91                       40.95                              1.56
  Venlafaxine                          Yeast                2.76                        40.95                              3.89

###### 

Scaling factor with different enzymes and expression systems.

  Enzymes   Expression systems   Scaling factor (mean ± SD)   CV
  --------- -------------------- ---------------------------- ---------
  1A2       Baculovirus          1.493 ± 1.112                74.48%
  1A2       *E. coli*            −0.869                       ---
  1A2       Lymphoblastoid       −1.154                       ---
  1A2       Yeast                3.794                        ---
  2B6       Baculovirus          2.232 ± 3.756                168.28%
  2C8       Baculovirus          2.093 ± 2.588                123.65%
  2C9       Baculovirus          0.947 ± 3.490                368.53%
  2C9       *E. coli*            5.828                        ---
  2C9       Lymphoblastoid       1.530 ± 2.351                153.66%
  2C9       Yeast                1.894                        ---
  2C19      Baculovirus          −1.735 ± 1.716               98.90%
  2C19      Lymphoblastoid       1.181                        ---
  2D6       Baculovirus          2.394 ± 0.601                25.10%
  2D6       Lymphoblastoid       1.213 ± 0.790                65.13%
  2D6       *E. coli*            7.290                        ---
  2D6       Yeast                2.399 ± 2.111                87.95%
  3A        Baculovirus          −1.320 ± 2.653               200.98%
  3A        *E. coli*            −1.014                       ---
  3A        Lymphoblastoid       0.993 ± 3.541                356.60%
  3A        Yeast                1.038                        ---
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